THALES
10.4.2024 11:40:33 CEST | Business Wire | Press release
Thales, the leading global technology and security provider, today announced a collaboration leveraging its CipherTrust Data Security Platform (CDSP) to support End-To-End Data Protection (E2EDP) on Google Cloud, using Confidential Computing (CC) from Google Cloud and trusted cloud independent attestation provided by Intel Trust Authority (ITA).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410848317/en/
©Thales
The effort is a step forward in data security, giving enterprises additional controls to protect their data at rest, in transit, and in use.
“As more enterprises migrate their data and workloads to the cloud, there is an increasing demand to safeguard the privacy and integrity of the data, especially those sensitive workloads that include intellectual property, AI models and valuable personal information. This collaboration enables enterprises to protect and control their data at rest, in transit and in use with fully verifiable attestation. Our close collaboration with Google Cloud and Intel increases our customers' trust in their cloud migration,” said Todd Moore, Vice President of Data Security Products at Thales.
A majority of the 2023 Thales Cloud Security Study respondents reported having a significant amount of sensitive data stored and in use in the cloud. Consequently, safeguarding sensitive data and associated workloads when stored or in use, is an increasing priority, especially for highly regulated industries such as financial services and healthcare. Thales's collaboration with Intel and Google Cloud provides certifiable controls for enterprises to fully protect their data end-to-end.
Purnam Sheth, Vice President and General Manager: Trust and Security Products, SATG at Intel: “Creating this groundbreaking, seamless data security platform in Google Cloud meets customers’ complex requirements for data protection, controlled access and security, and adherence to compliance for data at rest, in transit and in use. Foundational Intel® Trust Domain Extensions Confidential Compute and Intel® Trust Authority gives enterprises assurance of the integrity of their workloads and guards at all stages of data management. This valuable collaboration between Thales, Google Cloud and Intel makes this possible.”
This security platform is based on the principle of separation of duties, where the customer remains in control of the encryption keys and their location. This approach enhances trust by holding each stakeholder responsible for their respective roles and reduces the ability for a malicious actor to access code and data at rest, in transit and while being executed.
Customers can migrate existing workloads with sensitive data or create new workloads needing zero trust, confidential computing and Confidential AI to this security platform in Google Cloud to broaden data security, attestation and set the right authorizations. With end-to-end data protection, multiple parties can securely collaborate on various use cases, such as Confidential AI datasets and models as needed while preserving privacy, confidentiality, and compliance with privacy regulations.
The Thales CipherTrust Data Security Platform uses Intel Trust Authority as a zero-trust, independent attestation service for advanced security and scalable confidential computing. Consistent attestation to Trusted Execution Environments (TEE) that are based on Intel Trust Domain Extensions. This single, consistent attestation process provides assurance to any relying party that the TEE and any data and workloads running within it have not been compromised.
Brian Roddy, VP, Product Management, Google Cloud: “Google Cloud is committed to providing our customers secure, private and reliable environments for their workloads, and our Confidential Computing portfolio plays a critical role in this effort. Offering our customers solutions like Thales’ encryption key management expertise, combined with Intel’s Trust Authority attestation, enables the choice of even stronger privacy controls.”
The collaboration comes as Thales is recognized for its achievements in the Google Cloud ecosystem. For the second year in a row, Thales has received the 2024 Google Cloud Technology Partner of the Year Award for Security - Data Protection.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies within three domains: Defence & Security, Aeronautics & Space, and Cybersecurity and Digital Identity. It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key areas such as quantum technologies, Artificial Intelligence, Edge computing, 6G and cybersecurity.
Thales has 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
* These figures exclude the ground transportation business, which is being divested
PLEASE VISIT
Cloud Protection & Licensing Solutions | Thales Group
Cybersecurity Solutions | Thales Group
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410848317/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
